Image (D78873c1 29ce 478b Aa3d D1a11a2750ce 01)
Citalopram Tablet
Product Images NDC 50090-5175
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Citalopram (NDC 50090-5175). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Image (D78873c1 29ce 478b Aa3d D1a11a2750ce 02)
This table shows the drug-placebo difference in the number of cases of suicidal behavior per 1000 patients treated, categorized by age range. For patients under 18 years old, there were 14 additional cases of suicidal behavior compared to placebo. For patients over 18 years old, there were decreases in the number of cases compared to placebo, with 564 fewer cases for one drug and 265 fewer cases for another drug.*
Image (D78873c1 29ce 478b Aa3d D1a11a2750ce 03)
This is a table showing the incidence of treatment-emergent adverse events in placebo-controlled clinical trials of Citalopram. The table shows the percentage of patients reporting adverse events in various body systems, such as the autonomic nervous system, central and peripheral nervous system, gastrointestinal system, musculoskeletal system, psychiatric disorders, respiratory system disorders, and urogenital system. The adverse events reported by at least 2% of patients treated with Citalopram are mentioned. The denominator used was for females and males separately in different adverse events.*
Image (D78873c1 29ce 478b Aa3d D1a11a2750ce 04)
This is a table showing the percentage of patients discontinuing the treatment due to adverse events in short-term, placebo-controlled depression trials. The table includes the body system or adverse event and the corresponding percentage for patients taking Citalopram and those on Placebo. The body systems and adverse events listed include General, Gastrointestinal Disorders, Central and Peripheral Nervous System Disorders, and Psychiatric Disorders. There is no non-English character present in the text.*
Label Image (Lbl500905175)
This is a medication bottle of Citalopram, a drug commonly used to treat depression and anxiety disorders with a strength of 40mg per tablet. The bottle contains 160 tablets and has a label with the name "Stone Rook" on it. The code "Panau:t‘fio 5627-1" represents a unique identifier but its meaning is not clear without further context.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
